Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q9UM73
UPID:
ALK_HUMAN
Alternative names:
Anaplastic lymphoma kinase
Alternative UPACC:
Q9UM73; A6P4T4; A6P4V4; Q4ZFX9; Q53QQ6; Q53RZ4; Q59FI3; Q9Y4K6
Background:
The ALK tyrosine kinase receptor, also known as Anaplastic lymphoma kinase, plays a pivotal role in the development and differentiation of the nervous system. It is transiently expressed in specific regions of both the central and peripheral nervous systems. ALK functions as a neuronal receptor tyrosine kinase, crucial for the genesis of the nervous system. It also acts as a key regulator in energy homeostasis, controlling energy expenditure and resistance to weight gain.
Therapeutic significance:
ALK's involvement in neuroblastoma 3, a common early childhood neoplasm, underscores its therapeutic significance. Disease susceptibility is linked to genetic variants affecting ALK, highlighting its potential as a target for therapeutic intervention in neuroblastoma treatment.